RT Journal Article SR Electronic T1 Development of a new Aerosol Barrier Mask for mitigation of spread of SARS-CoV-2 and other infectious pathogens JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.11.21251593 DO 10.1101/2021.02.11.21251593 A1 Karam Abi Karam A1 Piyush Hota A1 S. Jimena Mora A1 Amelia Lowell A1 Kelly McKay A1 Xiaojun Xian A1 Bhavesh Patel A1 Erica Forzani YR 2021 UL http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251593.abstract AB The COVID-19 pandemic has caused huge impact on public health and significantly changed our lifestyle. This is due to the fast airborne oro-nasal transmission of SARS-CoV-2 from the infected individuals. The generation of liquid aerosolized particles occurs when the COVID-19 patients speak, sing, cough, sneeze, or simply breathe. We have developed a novel aerosol barrier mask (ABM) to mitigate the spread of SARS-CoV-2 and other infectious pathogens. This Aerosol Barrier Mask is designed for preventing SARS-CoV-2 transmission while transporting patients within hospital facilities. This mask can constrain aerosol and droplet particles and trap them in a biofilter, while the patient is normally breathing and administrated with medical oxygen. The system can be characterized as an oxygen delivery and mitigation mask which has no unfiltered exhaled air dispersion. The mask helps to prevent the spread of SARS-CoV-2, and potentially other infectious respiratory pathogens and protects everyone in general, especially healthcare professionals.Competing Interest StatementAll authors, except Xiaojun Xian and Erica Forzani, declare no conflict of interest. XX and EF are associated with TF Health Co. (d.b.a. Breezing Co.).Funding StatementThe authors acknowledge SEMTE, ASU, Mayo Clinic, Biodesign Institute, and NIH R03 funding from NIBIB (EB027336-02)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of Arizona State University (IRB reference protocols # STUDY00006547).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is in our possession and available if is required